|
||
 |
||
 |
||
|
Theravance has a collaboration arrangement with Astellas Pharma Inc. (Astellas) for the global development and commercialization of telavancin. Telavancin is a rapidly bactericidal, injectable antibiotic with a multifunctional mechanism of action. Telavancin inhibits the formation of the bacterial cell wall and disrupts bacterial cell membrane function. We believe the additive mechanisms of action seen with telavancin speed bacterial killing while also reducing the risks of inducing resistance to telavancin or cross-resistance with other antibiotics.
Under the terms of the collaboration, Theravance will lead the development of and U.S. regulatory process for telavancin for the treatment of hospital-acquired pneumonia and complicated skin and skin structure infections, and will collaborate substantially with Astellas in marketing in the United States for the first three years. Astellas will lead all other development, regulatory, manufacturing, sales and marketing activities. |
|
| ©2008 Theravance, Inc. Theravance, the Theravance logo and Medicines That Make a Difference are
registered trademarks of Theravance, Inc. Trademarks, trade names or service marks of other companies appearing on this
website are the property of their respective owners. All rights reserved.
Terms of Use Website Admin Contact Theravance Contact Site Map |
||
|
|
|